GLP-1 Before and After: The Weight Loss Results to Realistically Expect

The honest version of GLP-1 before and after results is this: in the large trials, semaglutide produced about 14.9% mean body-weight loss over 68 weeks and tirzepatide up to about 20.9% over 72 weeks, but the change is gradual, it builds over more than a year, and it varies widely from person to person. The dramatic side-by-side photos that circulate online are the upper end of a wide distribution, not the average. This guide sets out what the GLP-1 weight loss results actually look like over time, when they start to show, what shapes them, and the one fact that gets left out of most before-and-after stories: the results last only as long as the treatment does.

No fake testimonials and no invented numbers appear below. Every figure comes from the published randomised trials that established these medications, and where individual experience departs from the averages, that is said plainly. The goal is to set expectations you can actually plan around.

What the GLP-1 before and after results actually show in trials

Two trials define the modern evidence base, and they are the right place to anchor any realistic before-and-after picture.

The STEP 1 trial randomised 1,961 adults with overweight or obesity, but without diabetes, to once-weekly semaglutide titrated to 2.4 mg or to placebo, alongside lifestyle support. Over 68 weeks, the semaglutide group lost a mean of about 14.9% of body weight, against roughly 2.4% on placebo. About 86% of those on semaglutide lost at least 5% of their body weight, and a substantial share reached 10%, 15%, and even 20%. The deeper detail of that trajectory sits in our piece on weight loss on semaglutide.

SURMOUNT-1 did the same for tirzepatide. It randomised 2,539 adults with obesity, or overweight with a weight-related complication, to one of three tirzepatide doses or placebo over 72 weeks. Mean weight loss was 15.0% on the 5 mg dose, 19.5% on 10 mg, and 20.9% on the highest 15 mg dose, against 3.1% on placebo. On the top dose, the average participant lost roughly a fifth of their starting weight, and more than half of those on the highest dose lost more than 20%. The mechanism behind that larger effect is covered in how tirzepatide works, and the parallel for semaglutide in how semaglutide works for weight loss.

Medication (trial)	Dose	Duration	Mean weight loss	Placebo
Semaglutide (STEP 1)	2.4 mg weekly	68 weeks	~14.9%	~2.4%
Tirzepatide (SURMOUNT-1)	5 mg weekly	72 weeks	~15.0%	~3.1%
Tirzepatide (SURMOUNT-1)	10 mg weekly	72 weeks	~19.5%	~3.1%
Tirzepatide (SURMOUNT-1)	15 mg weekly	72 weeks	~20.9%	~3.1%

Put plainly: a realistic GLP-1 before and after target is something like 15% of body weight on semaglutide and up to about 20% on high-dose tirzepatide, achieved over roughly 14 to 17 months, not weeks. For someone starting at 220 pounds, 15% is around 33 pounds and 20% is around 44 pounds. Those are large, clinically meaningful changes, and they are also slower and less photogenic than the marketing suggests.

The GLP-1 before and after timeline: when results show

The single most useful thing to understand about GLP-1 weight loss results is the shape of the curve. It is not linear. Treatment starts at a low dose and steps up over months, the steepest loss tends to come in the first half of the year, and the curve flattens as the body adapts. The table below describes the typical pattern drawn from how the trial curves behaved, not a guarantee for any one person.

Phase	Roughly when	What usually happens
Titration / ramp	Weeks 1 to 16	Dose climbs in steps. Appetite and "food noise" start to quiet. Early loss is modest while the dose builds.
Steepest loss	Months 4 to 9	On a therapeutic dose, the fastest, most visible weight loss tends to occur here.
Slowing	Months 9 to 14	Loss continues but decelerates as the body's defences engage.
Plateau / maintenance	~14 to 17 months on	Weight settles near a new equilibrium. Maintaining it becomes the task.

Two practical points follow. First, the early weeks underwhelm by design. Because treatment is titrated upward to limit side effects, the first month or two is mostly about reaching a dose that works, not about dramatic loss. Patience through the ramp is part of the process. Second, the trials ran for 68 and 72 weeks because that is roughly how long the loss took to level off. Judging your GLP-1 before and after results at week 6, or even month 3, measures the climb rather than the destination. For framing sensible targets before you start, see realistic weight loss goals on GLP-1.

Why GLP-1 weight loss results vary so much

Averages hide enormous individual spread, and this is where before-and-after photos mislead most. In the trials, some participants lost a great deal, others relatively little, and a minority did not respond meaningfully at all. In STEP 1, while the mean was about 15%, the range around that mean was wide: plenty of people lost 20% or more, and some lost under 5%. The same was true across the SURMOUNT-1 doses.

So a real distribution of GLP-1 before and after results looks less like a single number and more like a spread:

• Strong responders: 20% or more of body weight. Real, and the source of the striking photos, but the high end, not the norm.
• Typical responders: roughly 10% to 20%. This is where most people land on an adequate dose taken consistently.
• Modest responders: 5% to 10%. Still clinically valuable for blood pressure, blood sugar, and joint load, even if the mirror change is subtle.
• Low responders: under 5%. A genuine minority. If you are here after reaching a full dose, it is worth reviewing with your clinician rather than concluding the drug "failed." We cover this in not losing weight on Ozempic.

The honest takeaway is that you cannot know in advance which group you will fall into. The trials establish what is possible at the population level, not what any single person should expect, and they do not predict responders ahead of time.

What affects your GLP-1 before and after results

Several factors shape where on that distribution a person lands. None is fully in your control, but several are.

Dose reached

SURMOUNT-1 showed the effect clearly: 15.0% at 5 mg versus 20.9% at 15 mg of tirzepatide. Reaching and tolerating a therapeutic dose matters. People who stall during titration, often because side effects were not managed, frequently never reach the dose that drives the bigger numbers.

Consistency and adherence

The trial results reflect weekly dosing taken consistently across more than a year. Missed doses, long gaps, and supply interruptions all blunt the curve. The before-and-after results in the data are the results of staying on treatment as prescribed.

The medication itself

Tirzepatide produced a larger average effect than semaglutide in their respective trials, which is one reason it draws so much interest. Both produce clinically meaningful loss; the dual-agonist mechanism simply reached a higher average ceiling.

Diet, protein, and muscle

The trials paired medication with lifestyle support, and that pairing matters for the quality of the result, not just the quantity. When intake falls sharply, protein often suffers and lean muscle can be lost alongside fat. Protecting muscle with adequate protein and resistance training is what keeps a before-and-after a healthy change rather than just a smaller number on the scale.

Starting point and biology

Baseline weight, metabolic profile, and individual biology all influence the response in ways the trials could not fully predict. Percentage loss is the fairer yardstick than pounds, because the same percentage means a different absolute change at different starting weights.

Plateaus: a normal part of the GLP-1 before and after story

Nearly every GLP-1 before and after trajectory includes a plateau, and it is not a sign of failure. As weight comes off, the body mounts a coordinated defence: hunger signalling rises, satiety signalling falls, and resting energy expenditure drops by more than body-size change alone would predict. Eventually that defensive reduction in energy use meets the medication's effect on appetite at a new equilibrium, and the scale stops moving. This is the same biology that defends weight after any form of weight loss, not a quirk of the drugs.

Understanding this changes how you read your own results. A plateau after a year is the expected end of the steep phase, not evidence the medication stopped working. The mechanics, and what can and cannot be done about it, are covered in detail in the GLP-1 weight loss plateau guide.

The fact most before-and-after stories leave out: results depend on continued use

This is the part that almost never appears beside a transformation photo, and it is the most important context for any GLP-1 before and after picture. The results are tied to ongoing treatment.

The STEP 4 trial showed this directly. All participants took semaglutide for an initial 20 weeks, then were randomised either to continue or to switch to placebo for a further 48 weeks. The continuation group lost an additional 7.9% of body weight. The placebo group regained an average of 6.9%, roughly two-thirds of what they had lost during the run-in. The STEP 1 trial extension, which followed participants after the drug was withdrawn, found the same pattern: much of the lost weight returned over the following year, and the cardiometabolic improvements partly reversed alongside it.

The reason is biological, not behavioural. These medications counter the body's defence of its prior weight; they do not erase it. While the drug is present, elevated hunger is suppressed and satiety is restored. When it is withdrawn, the underlying disposition reasserts itself, the same way blood pressure rises again when antihypertensive medication is stopped. So an honest before-and-after is really a before, during, and "for as long as treatment continues." Planning for that horizon up front, rather than treating the medication as a short course, is the difference between keeping the result and watching it reverse. We work through that in planning for life after a GLP-1.

Setting honest expectations and getting started

If you are weighing whether to start, the realistic before-and-after picture is encouraging on its own terms: roughly 15% of body weight on semaglutide and up to about 20% on high-dose tirzepatide, built steadily over more than a year, with wide individual variation and a result that holds while treatment continues. That is a clinically meaningful change that diet and exercise alone rarely sustain at the same magnitude, which is exactly why these drugs reset the field. It is also not a quick fix, not a guarantee of the upper-end photo, and not a one-time course.

Getting started usually begins with an eligibility assessment, a prescription, and a titration plan, then consistent dosing and follow-up. Many people now begin through a licensed online telehealth provider, which can handle the evaluation, prescribing, and monitoring without a traditional in-person referral, often with faster access to a clinician who manages the titration and side effects that determine whether you reach an effective dose. A provider that evaluates you properly, prescribes an FDA-approved product, and stays reachable for follow-up is what turns the trial numbers above into a real-world result. The mechanism, the evidence, and the trade-offs are all laid out in our complete guide to GLP-1 medications.

Key takeaways

• Realistic GLP-1 before and after results: about 14.9% mean loss on semaglutide over 68 weeks (STEP 1) and up to about 20.9% on tirzepatide over 72 weeks (SURMOUNT-1).
• The change is gradual. The steepest loss comes in roughly months 4 to 9, and the curve flattens toward a plateau around 14 to 17 months.
• Individual results vary widely, from over 20% loss to under 5%. The trials cannot predict in advance who lands where.
• Dose reached, consistency, the specific medication, diet and protein, and baseline biology all shape the outcome.
• A plateau is a normal, expected part of the trajectory, driven by the body's defence of its weight, not a sign of failure.
• Results depend on continued use. STEP 4 showed roughly two-thirds of lost weight returns after stopping, so plan for the long term.